Enzene Biosciences raises $50 million, aims to expand into global markets

Enzene said it has built a highly experienced 400-person team under the leadership of Dr. Himanshu Gadgil, CEO at Enzene Biosciences Ltd

bank, credit, growth, loans, funding, capital, cash, m&a, payment
Premium

The newly raised funds will be used to enhance manufacturing capabilities

Peerzada Abrar Bengaluru
Enzene Biosciences Ltd (‘Enzene’), a biotech company and a subsidiary of Alkem Laboratories Ltd., said that it has raised $50 million from Alkem Laboratories Ltd. and new investors, Eight Roads Ventures and F-Prime Capital.

The newly raised funds will be used to enhance manufacturing capabilities and drive expansion plans both in India and in the US.

Enzene said it has successfully leveraged its platform to develop a captive pipeline of biosimilars. These have been out-licensed to pharmaceutical companies across global markets while also offering end-to-end contract development and manufacturing (CDMO) services to biotechnology companies.

Enzene said it has built

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 30 2023 | 6:15 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com